Jiri Masin

This inventor holds 3 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Institut Pasteur, Institute of Microbiology of the Ascr, V.v.i., Institute of Physiology of the Ascr, V.v.i.. Active years: 2011-2017.

USPTO Granted Patents = 3 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

Institute of Microbiology of the Ascr, V.v.i.

patents

2 out of 2

Institute of Physiology of the Ascr, V.v.i.

patents

where one patent can have more than one assignee

Years Active: 2011-2017

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9708596 - Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell (2017-07-18),

2. 9222143 - Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell (2015-12-29),

3. 8017132 - Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell (2011-09-13),

Title: Jiri Masin: Innovator in Immunogenic Delivery Systems

Introduction

Jiri Masin is a notable inventor based in Uvaly, Czech Republic. He has made significant contributions to the field of immunology through his innovative work on polypeptides. With a total of 3 patents, Masin's inventions focus on enhancing the delivery of immunogenic molecules into cells.

Latest Patents

One of Masin's latest patents is centered around mutant CyaA polypeptides and their derivatives. This invention relates to the use of mutant CyaA/E570Q+K860 polypeptides as proteinaceous vectors for delivering molecules of interest into cells, particularly those expressing the CD11b receptor. The polypeptides are designed to elicit an immune response while retaining the binding activity of native CyaA. Furthermore, these mutant polypeptides exhibit reduced pore-forming activity compared to the native CyaA toxin, making them safer for therapeutic applications.

Career Highlights

Throughout his career, Jiri Masin has worked with prestigious institutions such as Institut Pasteur and the Institute of Microbiology of the ASCR, v.v.i. His research has significantly advanced the understanding of immunogenic delivery systems, contributing to the development of novel therapeutic strategies.

Collaborations

Masin has collaborated with esteemed colleagues in the field, including Peter Sebo and Claude Leclerc. These partnerships have fostered a collaborative environment that enhances research outcomes and innovation.

Conclusion

Jiri Masin's work in the field of immunogenic delivery systems exemplifies the impact of innovative research on healthcare. His contributions through patents and collaborations continue to pave the way for advancements in immunology.